GLP-1 Receptor Agonists May Reduce Dementia Risk in Patients with Kidney Disease and Type 2 Diabetes

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia and Alzheimer’s disease in individuals with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), according to recent research. This finding is particularly significant given the increased risk of cognitive decline faced by those with both conditions.

The Link Between Kidney Disease, Diabetes, and Cognitive Decline

Patients with CKD and T2DM are at a higher risk of cognitive decline due to factors like vascular dysfunction, insulin resistance, and chronic inflammation. Although GLP-1RAs are well-established treatments for managing blood sugar and have demonstrated benefits for cardiovascular and kidney health, emerging evidence suggests they may as well offer neuroprotective effects.

Study Findings: GLP-1RAs vs. DPP4i

A retrospective cohort study analyzed electronic health record data from the TriNetX global research network, encompassing 67 healthcare organizations across the USA. Researchers identified adults with CKD stage 3 or later and T2DM who were newly prescribed either a GLP-1RA or a dipeptidyl peptidase-4 inhibitor (DPP4i) between January 2015 and December 2020. Patients with prior exposure to either drug class, a recent dementia diagnosis, or recent hospitalization were excluded.

The primary outcome measured was the incidence of dementia over a follow-up period of 90 days to five years. Subtypes of dementia assessed included Alzheimer’s disease, vascular dementia, frontotemporal dementia, Parkinson’s disease, extrapyramidal and movement disorders, and dementia with Lewy bodies.

Compared to DPP4i use, GLP-1RA therapy was associated with a 20% lower risk of overall dementia (hazard ratio [HR] 0.80; 95% CI 0.71–0.91; p=0.001). Specifically, the risk of Alzheimer’s disease was reduced by 24% (HR 0.76; 95% CI 0.59–0.98; p=0.033). No statistically significant differences were observed for other neurodegenerative outcomes, such as vascular dementia or Parkinson’s disease.

How GLP-1RAs May Protect the Brain

The authors propose that GLP-1RAs may provide neuroprotective benefits beyond their impact on blood sugar control. These therapies appear to have pleiotropic effects, meaning they influence multiple biological pathways. While this study’s observational design doesn’t prove a direct cause-and-effect relationship, the findings contribute to a growing body of evidence supporting the broader benefits of GLP-1-based therapies.

Future Research and Clinical Implications

Further prospective studies are needed to confirm these associations and determine the optimal treatment strategies for patients with CKD and diabetes who are at risk of cognitive decline. Understanding the mechanisms behind these neuroprotective effects could lead to new approaches for preventing and treating dementia in this vulnerable population.

Additional Information

GLP-1 RAs help slow CKD and lower heart disease risk for people with type 2 diabetes and/or obesity, but it’s important to weigh risks and benefits. National Kidney Foundation

GLP-1 receptor agonists (GLP-1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes (T2DM) with chronic kidney disease (CKD). Wiley Online Library

GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. National Library of Medicine

The REMODEL study clarified which pathways are responsible for semaglutide’s cardiorenal effects in patients with CKD and type 2 diabetes. Renal and Urology News